Treatment of Post-Thrombolysis sICH Doesn't Lower Mortality

This article originally appeared here.
Share this content:
Treatment of Post-Thrombolysis sICH Doesn't Lower Mortality
Treatment of Post-Thrombolysis sICH Doesn't Lower Mortality

WEDNESDAY, Oct. 28, 2015 (HealthDay News) -- Treatment of thrombolysis-related symptomatic intracerebral hemorrhage (sICH) does not reduce in-hospital mortality, according to a study published online Oct. 26 in JAMA Neurology.

Shadi Yaghi, M.D., from the Columbia University Medical Center in New York City, and colleagues conducted a multicenter retrospective study at 10 primary and comprehensive stroke centers to better understand the natural history of thrombolysis-related sICH.

Overall, 128 patients (3.3 percent) of the 3,894 treated with intravenous recombinant tissue plasminogen activator (rtPA) within 4.5 hours after ischemic stroke symptoms onset had sICH. The researchers found that the median time from rtPA therapy initiation to sICH diagnosis was 470 minutes, and from sICH diagnosis to treatment was 112 minutes. The rates of in-hospital mortality and hematoma expansion were 52.3 and 26.8 percent, respectively. The sole factor associated with increased in-hospital mortality was code status change to comfort measures after sICH diagnosis, in the multivariable models (odds ratio, 3.6). Severe hypofibrinogenemia correlated with hematoma expansion and was seen in 36.3 and 25.0 percent of those without and with hematoma expansion, respectively (P = 0.01).

"In this study, treatment of post-thrombolysis sICH did not significantly reduce the likelihood of in-hospital mortality or hematoma expansion," the authors write. "Shortening the time to diagnosis and treatment may be a key variable in improving outcomes of patients with sICH."

Several authors disclosed financial ties to the medical device industry.

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »